Small Molecule LCDM and GV Oocyte

Assisted Reproduction Clinical Trial

Official title: Study on the Effectiveness of Small Molecule LCDM Combined With Oocyte Activation in Improving GV Oocyte in Vitro Maturation

Status Not yet recruiting

Clinical Trial Summary

Immature eggs obtained during the oocyte retrieval cycle are discarded as medical waste because they cannot complete fertilization, but each egg is important for people with poor clinical outcome. In vitro maturation (IVM) technique allows immature GV and MI eggs to mature in vitro, offering hope for this population to increase the clinical pregnancy rate in a single oocyte retrieval cycle. However, the clinical effectiveness of IVM clinical application is still very low, especially the utilization rate of GV eggs is extremely low. The cocktail of small molecules includes four chemical components of LCDM, which are related to cell proliferation, in vitro maturation of eggs, and protection of cells from oxidative stress. Our preliminary experiments confirmed that the addition of a certain concentration of LCDM in the culture medium can significantly improve the in vitro maturation rate and embryo utilization rate of immature GV eggs. In this study, LCDM immature oocyte culture system was used to carry out in vitro maturation culture of GV oocytes, and combined with oocyte activation technology to verify the clinical safety of LCDM in vitro culture system by observing the in vitro maturation rate, fertilization rate and embryo development results of GV oocytes, so as to provide laboratory data for clinical application of GV oocytes in special patients.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Assisted Reproduction

• NCT number: NCT05356429
• Study type: Observational
• Source: Peking University People's Hospital
• Contact: Xi Chen, Ph.D
• Phone: +86 18600634715
• Email: chenxi@pkuph.edu.cn
• Status: Not yet recruiting
• Start date: May 1, 2022
• Completion date: December 31, 2023